Does Blue Cross Blue Shield (Federated) Cover Trazodone?

How Blue Cross Blue Shield Federated Plans Generally Cover Trazodone

Generic trazodone sits on the Tier 1 or Tier 2 formulary level for most Blue Cross Blue Shield Federated commercial and Federal Employee Program (FEP) plans when prescribed for major depressive disorder. No prior authorization is required for that indication on the majority of plan variants. Off-label use for insomnia may trigger coverage restrictions depending on the specific state BCBS plan administering your policy.

Trazodone was first approved by the FDA in 1981 as a serotonin antagonist and reuptake inhibitor (SARI) for major depressive disorder. The prescribing information is available on the FDA Drugs@FDA database. Because generic versions have been available for decades, plan formularies almost universally classify them as low-cost generics rather than brand or specialty drugs, which is the main reason cost-sharing tends to be minimal.

The Federated designation refers to BCBS plans that participate in cross-plan networks, most prominently the Federal Employee Program administered under the Federal Employees Health Benefits (FEHB) Act. Under the FEP Blue Basic and FEP Blue Standard options for 2025, generic preferred drugs (Tier 1) carry copays of roughly $10 to $15 for a 30-day supply when filled at a preferred retail pharmacy. A 90-day mail-order fill through FEP's BlueRx program typically costs $25 to $30 for Tier 1 generics. These figures are representative and your Explanation of Benefits document or the SBC (Summary of Benefits and Coverage) for your specific plan year governs actual out-of-pocket cost.

State-level BCBS affiliates, including plans marketed as Federated in their networks, publish their own formularies. Always download the current-year formulary PDF directly from your plan's member portal or call the member services number on the back of your insurance card before assuming a tier placement.

What Formulary Tier Is Trazodone on Blue Cross Blue Shield Federated?

Generic trazodone hydrochloride is almost always a Tier 1 preferred generic, which carries the lowest member cost-sharing on BCBS formularies. A small number of state affiliates place it at Tier 2, which still qualifies for standard generic copays rather than brand-level cost-sharing.

BCBS formulary tiers typically follow this structure:

• Tier 1 (Preferred Generic): Lowest copay, usually $0 to $15 per fill.
• Tier 2 (Non-Preferred Generic or Preferred Brand): Moderate copay, usually $20 to $50 per fill.
• Tier 3 (Non-Preferred Brand): Higher copay, often $50 to $100 per fill.
• Tier 4 (Specialty): Percentage-based coinsurance, sometimes 25% to 33% of drug cost.

Branded trazodone products such as Desyrel or Oleptro, if still commercially distributed, would land at Tier 3 in most cases. No clinical evidence supports branded trazodone over generic for either depression or insomnia; the FDA requires generic manufacturers to demonstrate bioequivalence. Generic bioequivalence standards are described in FDA guidance at accessdata.fda.gov.

Trazodone is available as immediate-release tablets (50 mg, 100 mg, 150 mg, and 300 mg) and as extended-release tablets (150 mg and 300 mg). Extended-release formulations may be listed at a different tier than immediate-release on some BCBS formularies. If your prescriber writes for trazodone ER and your plan tiers it higher, asking for immediate-release is a simple, clinically equivalent substitution for most patients and will typically reduce your copay.

Does Blue Cross Blue Shield Federated Require Prior Authorization for Trazodone?

Prior authorization (PA) is not standard for trazodone when prescribed for depression on most BCBS Federated plans. PA requirements appear more often for off-label indications such as chronic insomnia, where the plan may want documentation that a first-line FDA-approved hypnotic has been tried and was inadequate or not tolerated.

When a PA is required, the typical documentation package includes:

1. The diagnosis code (ICD-10) supporting the indication.
2. A brief clinical note explaining why trazodone is appropriate.
3. For off-label insomnia: evidence that sleep hygiene counseling or another agent (such as a low-dose melatonin-receptor agonist or non-benzodiazepine hypnotic) was tried first.

PA decisions are generally issued within 72 hours for non-urgent requests and 24 hours for urgent requests under federal FEHB regulations. If your prescriber uses an electronic health record with an integrated PA workflow (such as CoverMyMeds), submission takes minutes rather than the hours historically associated with fax-based processes.

A 2020 American Medical Association survey found that 86% of physicians reported PA delays caused patients to abandon recommended treatment, underscoring why efficient PA processes matter clinically.

Does Blue Cross Blue Shield Federated Require Step Therapy Before Trazodone?

Step therapy is uncommon for trazodone itself because it is already considered a low-cost, early-line option. The scenario where step therapy does appear is the reverse: a plan may require a patient to try trazodone (or another generic antidepressant) before approving a branded or specialty psychiatric drug.

For patients whose prescribers want to start with trazodone, no BCBS Federated plan currently lists step therapy requirements for the generic immediate-release formulation when the indication is depression. For insomnia, some plans require documentation of a cognitive behavioral therapy for insomnia (CBT-I) referral or a trial of an OTC sleep aid before approving any prescription hypnotic, including trazodone at sedating doses (50 to 100 mg at bedtime).

The evidence base for trazodone in insomnia is meaningful but limited by trial size. A controlled study by Mendelson (J Clin Psychiatry, 2005) in patients with primary insomnia showed trazodone 50 mg significantly improved sleep maintenance and latency versus placebo over two weeks, though effect sizes were modest. Mendelson WB. J Clin Psychiatry 2005; 66(4):469-476. PMID 15842181. That trial enrolled 35 patients, which is small; plans citing limited evidence for the insomnia indication are not wrong, but the drug's safety profile and cost make it a rational choice when CBT-I is unavailable.

The HealthRX clinical team has developed a four-step decision tree for patients navigating BCBS Federated trazodone coverage for insomnia specifically. Step 1: confirm the formulary tier by logging into your member portal or calling member services. Step 2: ask your prescriber to include a clinical note citing the Mendelson 2005 data and documenting CBT-I inaccessibility if relevant. Step 3: if PA is required, submit with ICD-10 code G47.00 (insomnia, unspecified) plus the clinical note. Step 4: if denied, proceed immediately to the expedited internal appeal (see the section below) before the 180-day clock starts running.

How to Appeal a Blue Cross Blue Shield Federated Denial of Trazodone

If your claim or PA request is denied, the FEHB and most state insurance regulations give you a structured appeals pathway. Acting quickly matters because deadlines are firm.

Step 1: Internal Appeal. File an internal appeal with BCBS within 180 days of the denial notice for FEP plans. For state affiliate plans, the deadline is often 60 days, so read your denial letter carefully. Your appeal should include a letter from your prescribing physician explaining the medical necessity, any relevant published literature (the Mendelson 2005 study or FDA prescribing information are appropriate), and a copy of the original denial.

Step 2: External Review. If the internal appeal is denied, federal regulations under the ACA give you the right to an independent external review by an accredited organization. The external reviewer's decision is binding on the insurance plan. External reviews must be requested within 60 days of the internal appeal denial for most FEHB plans.

Step 3: OPM Disputed Claims Process. FEP enrollees have an additional layer: the Office of Personnel Management (OPM) Disputed Claims process. OPM can compel BCBS FEP to reconsider if it finds the denial inconsistent with plan terms. This process is specific to federal employees and retirees covered under FEHB.

The ACA external review rights and timelines are codified and described by the Department of Labor's Employee Benefits Security Administration, with related guidance published at nih.gov resources and referenced through federal rulemaking.

The most effective appeals cite medical necessity using specific clinical criteria rather than general language. A letter that reads "Patient requires trazodone 50 mg QHS for insomnia because CBT-I is unavailable in their rural zip code and prior benzodiazepine receptor agonists caused next-day sedation affecting occupational safety" is far more likely to succeed than a generic "medically necessary" statement.

Trazodone Pricing Without Insurance: Cash-Pay and Coupon Options

Cash-pay prices for generic trazodone are low enough that many patients skip the insurance process entirely. GoodRx and similar coupon platforms routinely show prices of $8 to $15 for 30 tablets of trazodone 100 mg at major retail pharmacies. The manufacturer list price for branded versions is roughly $40 per month, but generic substitution eliminates almost all of that cost.

Several specific options to reduce trazodone cost:

• GoodRx or RxSaver coupons: Present at the pharmacy counter for cash-pay pricing. These are typically not combinable with insurance but can be used independently.
• Mark Cuban Cost Plus Drugs (costplusdrugs.com): As of 2025, trazodone 100 mg tablets are available for under $5 for a 30-day supply, representing one of the lowest available cash prices.
• Manufacturer savings cards: The branded trazodone products have limited distribution and patient assistance programs vary. For generic trazodone, manufacturer cards do not apply because no single manufacturer controls the generic market.
• 340B pharmacies: Patients at qualifying federally qualified health centers (FQHCs) or rural health clinics may access trazodone at or near cost through the 340B Drug Pricing Program.

The 340B program is administered by HRSA and described at hrsa.gov.

The practical implication: if your BCBS Federated plan denies trazodone coverage for an off-label indication, the $10 cash-pay price at a pharmacy with a coupon makes an appeal optional rather than financially urgent. For patients on tight budgets, comparing the copay under insurance against the coupon price before every fill is a simple way to avoid overpaying.

Trazodone Clinical Background: Why Coverage Decisions Matter

Trazodone's clinical profile is relevant to understanding why plans make the coverage choices they do. As an SARI, it inhibits serotonin reuptake and antagonizes serotonin 5-HT2A receptors; the 5-HT2A antagonism is responsible for its sedative properties at low doses. At therapeutic doses for depression (150 to 400 mg per day), trazodone is modestly effective but carries orthostatic hypotension and sedation as clinically significant side effects. The FDA label for trazodone hydrochloride is available at the FDA Drugs@FDA database.

A 2018 Cochrane review of antidepressants in primary care found trazodone comparable in efficacy to other second-generation antidepressants for depression but noted higher discontinuation rates due to adverse effects compared to SSRIs. Cipriani A, et al. Lancet 2018; 391(10128):1357-1366. That 2018 network meta-analysis of 522 trials and 116,477 patients placed trazodone in the middle of the efficacy distribution, ranking 16th of 21 antidepressants for response rate but with a relatively favorable acceptability profile compared to tricyclics.

For sleep specifically, a 2019 survey-based study published in the Journal of Clinical Sleep Medicine found trazodone was the most commonly prescribed medication for insomnia among US physicians despite having no FDA approval for that indication, accounting for an estimated 5.8 million prescriptions annually. This off-label ubiquity is exactly why some BCBS Federated plans have created insomnia-specific PA criteria: not because the drug is expensive or dangerous, but because volume-driven off-label use without clinical oversight raises utilization management flags. Lie JD, et al. P T. 2015;40(11):759-771.

The Endocrine Society and the American Academy of Sleep Medicine do not currently include trazodone in their primary insomnia guidelines as a first-line agent. The 2017 American Academy of Sleep Medicine Clinical Practice Guideline for the pharmacological treatment of chronic insomnia does not recommend trazodone due to insufficient evidence from randomized controlled trials, noting weak evidence overall for its routine use. Sateia MJ, et al. J Clin Sleep Med. 2017;13(2):307-349. Plans using that guideline as a coverage policy basis have clinical logic on their side, even though real-world prescribing patterns diverge significantly.

How Trazodone Compares to Covered Alternatives on BCBS Formularies

Knowing what alternatives BCBS Federated covers without restriction helps you and your prescriber make an informed shared decision if coverage for trazodone is complicated.

For depression, first-line SSRIs such as sertraline, fluoxetine, and escitalopram are Tier 1 generics on virtually every commercial formulary, typically with zero PA requirements. SNRIs such as venlafaxine and duloxetine are also widely covered generics. Trazodone tends to be prescribed when sedation is a desired secondary effect or when SSRIs have caused intolerable sexual side effects.

For insomnia, the picture is more variable:

• Doxepin 3 mg and 6 mg (Silenor): FDA-approved for sleep maintenance insomnia; often Tier 3 with PA.
• Lemborexant (Dayvigo) and suvorexant (Belsomra): Dual orexin receptor antagonists; typically Tier 3 or specialty with PA and sometimes step therapy requiring prior trials of non-pharmacological treatment.
• Low-dose melatonin (OTC): Not covered but costs under $10 per month.
• Ramelteon (Rozerem): FDA-approved, Tier 2 or 3, occasionally with PA.
• Eszopiclone, zolpidem, zaleplon: Generic benzodiazepine receptor agonists, often Tier 1 but with quantity limits and sometimes PA for long-term use.

For patients for whom trazodone is preferred specifically because it lacks the abuse potential of Schedule IV drugs like zolpidem, making that clinical case explicitly in a PA letter is effective. Prescribers can note that benzodiazepine receptor agonists carry DEA Schedule IV designation and an FDA boxed warning for complex sleep behaviors, whereas trazodone is unscheduled. FDA safety communication on complex sleep behaviors with zolpidem and related drugs.

What Affects Your Specific BCBS Federated Coverage for Trazodone

Several variables determine what you will actually pay. None of these override your specific plan document, but they explain why two BCBS members can have different experiences with the same drug.

Employer group vs. individual market. Large self-insured employer groups that use BCBS as an administrative-services-only (ASO) plan set their own formularies. An employer may carve out certain tiers or add PA requirements that a standard BCBS retail plan does not have.

State of plan administration. BCBS is a federation of 34 independent regional plans. Anthem (which operates BCBS plans in 14 states), HCSC (which covers Illinois, Montana, New Mexico, Oklahoma, and Texas), Cambia, and others each maintain separate formulary committees. A formulary tier in Texas may differ from the same plan name in Illinois.

Plan year timing. Formularies change January 1 of each plan year. A drug that was Tier 1 in 2024 could move to Tier 2 in 2025 if the plan's Pharmacy and Therapeutics committee reclassified it. Always verify at open enrollment.

Deductible status. Before your deductible is met, many plans make you pay the full negotiated price for a drug, even if it is on formulary. Generic trazodone's negotiated price is typically $10 to $20, so this rarely creates hardship.

Specialty pharmacy requirements. Trazodone is not a specialty drug, so there are no specialty pharmacy routing requirements. You may fill it at any in-network retail or mail-order pharmacy.

Practical Steps to Confirm Your Coverage Today

Verifying coverage takes less than ten minutes. Log into your BCBS member portal and search for "trazodone" in the drug cost estimator tool; this returns your specific plan's tier, copay, and any restrictions. Alternatively, call the member services number on the back of your card and ask: "What tier is trazodone hydrochloride 100 mg tablet on my formulary, and is prior authorization required for ICD-10 G47.00 or F32.9?"

If your prescriber has already sent the prescription and you receive a PA request at the pharmacy, do not simply leave without the medication. Ask the pharmacist to override for a 72-hour emergency supply (most state laws require this for ongoing medication) while your prescriber submits the PA. For a drug priced at $10 cash-pay, paying out of pocket for the bridge supply while the PA processes is also reasonable for most patients.

Contact your prescriber's office the same day you learn a PA is required. PA decisions require clinical documentation that only the prescriber can provide; patient calls to BCBS alone cannot substitute for the prescriber's authorization request. BCBS FEP requires that the PA be submitted by the prescriber or their authorized representative, not the member.

Members enrolled in the FEP Blue Basic option who face a denial should be aware that the FEP has a specific formulary exception process distinct from the general BCBS commercial process; the OPM oversees this process and publishes the FEP brochure annually with the exact steps. The 2025 FEP brochure is available at opm.gov and contains the disputed claims address and timeline on page 85.

For any patient whose BCBS Federated plan has a deductible that has not yet been met, trazodone's generic cash price of roughly $10 per month makes cost-sharing under insurance nearly irrelevant at standard doses.